Current Issue : January - March Volume : 2021 Issue Number : 1 Articles : 5 Articles
Treatment of patients with severe COVID-19, is challenging specifically when\na patient carries high risk of mortality, such as old age, immune suppression\nor cancer. Also a patient who manifests the disease with severe symptoms,\nsuch as hypoxia, requiring supplemental oxygenation, or artificial ventilation\nhas a poor prognosis. Here we review the scientific rationale used to design a\nvery promising therapy based on existing literature, but in significantly different\nmethod and protocols, used to treat cases of severe COVID-19, and we\nconclude that although the effort on drug development has been enormous,\nbut as of today, we do not have a therapy with specific characteristics as this\nprotocol, to be used safely in human and yet potentially meet the expectations\nwe would have for a so called â??effective therapyâ?. Further clinical trials are\nneeded to support this hypothesis and generate further hypothesis to prove\nthe concept in larger cohort of patients....
A number of companies have announced the vaccines for COVID-19 pandemic\nthat has caused extreme poverty, famine, and more than a billion people\nhave lost livelihood all across the globe. Mass production of vaccine Sputnik\nV is underway at different locations to inoculate population in Russia, Philippines,\nVietnam, Brazil, Saudi Arab, and United Arab Emirates (UAE), and\nIndia. mRNA based vaccine of Pfizer-BioNTech after passing phase 2 trial is\nready for testing on thousands of volunteers. Oxford University-AstraZeneca\nvaccine is also under phase 3 trial in US, Brazil, and India. In September, Novavax\nInc.â??s vaccine will be ready for phase 3 trial. By early next year, two billions\nof doses will be ready of Novavax. Moderna Therapeutics conducting\nvaccine trial on 30 thousands volunteers, results will be known soon.............................
COVID-19 is a new contagious, deadly viral/immunological systemic disorder\nwith predominantly respiratory features caused by human infection with\nSARS-CoV-2, which is rapidly spreading from person-to-person all around\nthe world as a pandemic, whereas, Allergic Rhinitis is an old non-contagious,\nnon-deadly, and non-viral disorder with nasal inflammation which occurs when\nthe immune system overreacts to allergens. Mild to moderate COVID-19 can\nbe mistaken with Allergic Rhinitis. Fever, dry cough, dyspnea, fatigue, body\nache, anosmia, and lack of taste are the cardinal feature of COVID-19, whereas\nrunny nose, stuffy nose, sneezing, postnasal discharge, itchy eyes, and\nitchy skin are the cardinal feature of Allergic Rhinitis. Some of the cardinal\nfeature of COVID-19 can be accessory feature of Allergic Rhinitis and vice\nversa . These two diseases are usually distinguishable by an expert physician.\nAt the same time, an inexperienced physician will easily confuse them. The\nknown cases of Allergic Rhinitis have allergies in this spring or year similar to\nprevious years, not COVID-19, unless this time the symptoms are sudden,\nnew, or more severe, and with previous conventional allergy treatment; donâ??t\ngive up and get even worse. In fact, the mission of this article is to provide the\neasiest way to differentiate these two diseases. In the SARS-CoV-2 epidemics\nin the Red zones, when we cannot differentiate these two diseases; Allergic\nRhinitis should be discarded in favor of COVID-19....
Background: The outbreak of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome\ncoronavirus 2 (SARS-CoV-2) is currently the peak season of common respiratory viral infections. However, the clinical\nsymptoms of most SARS-CoV-2 infected patients are not significantly different from those of common respiratory viral\ninfections. Therefore, knowing the epidemiological patterns of common respiratory viruses may be valuable to improve\nthe diagnostic and therapeutic efficacy of patients with suspected COVID-19, especially in Southwest China (a mild\nepidemic area).\nMethods: A total of 2188 patients with clinically suspected of COVID-19 in Southwest China were recruited from\nJanuary 21 to February 29, 2020. Nasopharyngeal swabs, throat swabs and sputum specimens were collected to detect\nSARS-CoV-2 by using real-time reverse transcription-polymerase chain reaction (RT-PCR) and other 12 viruses via PCR\nfragment analysis combined with capillary electrophoresis. Clinical characteristics and laboratory test findings were\nacquired from electronic medical records. All data were analyzed to unravel the epidemiological patterns.\nResults: Only 1.1% (24/2188) patients with suspected COVID-19 were eventually confirmed to have SARS-CoV-2\ninfection,............................
The corona virus disease 2019 (COVID-19) pandemic has spread globally and\npregnant women are considerably prone to COVID-19 infection with increased\nmaternal and perinatal complications. Aim: This study aims to explore\nthe risk factors that contribute to susceptibility and severity of\nCOVID-19 infection among pregnant women. Method: A literature search of\narticles relating to COVID-19 infection during pregnancy, was conducted,\nusing PubMed, Scopus and Google scholar engine. Result: A total of 168 articles\nwere initially identified. Eighty four papers were excluded for failing to\naddress the aim of the study. After screening titles and abstracts, eighty four\nfull-text articles were retrieved for eligibility analysis. Nineteen studies addressed\nthe susceptibility related to pregnancy, twenty-two studies evaluated\nthe associated comorbidities, nineteen focused on immune system, thirty-six\narticles concentrated on the risk of coagulopathy and eleven addressed more\nthan one risk factor. Conclusion: Pregnancy, associated comorbidities, modulated\nimmune response during pregnancy and risk of coagulopathy are considerable\nrisk factors contributing to COVID-19 pathogenesis among pregnant\nwomen and may predict the outcome....
Loading....